Condensed Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	3 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Cash flows provided by (used in) operating activities:
Net income	$ 7.3	$ 31.1
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	122.1	120.4
Amortization and write off of deferred financing costs	2.8	3.6
Stock-based compensation expense	3.6	4.2
Provision for (recovery) of doubtful accounts receivable	(1.0)	0.1
Deferred income taxes	(29.8)	(61.0)
Other	(3.6)	(3.9)
Changes in operating assets and liabilities, net of acquired assets:
Accounts receivable	40.9	8.0
Inventories	(36.7)	(7.5)
Prepaid expenses	20.6	2.3
Accounts payable	(14.0)	(19.6)
Income taxes	4.0	17.0
Accrued interest	(16.6)	(16.2)
Accrued wages and commissions	(48.2)	(34.8)
Accrued expenses and other	(49.0)	7.1
Net cash provided by operating activities	2.4	50.8
Cash flows provided by (used in) investing activities:
Proceeds from sales/maturities of investments	0	9.5
Purchases of investments	(16.3)	(9.5)
Net proceeds from sale of assets	0	0.2
Capital expenditures	(60.8)	(46.5)
Acquisitions, net of cash acquired	(0.3)	(0.4)
Net cash used in investing activities	(77.4)	(46.7)
Debt:
Payments under European facilities	0	(2.3)
Payments under senior secured credit facilities	(7.8)	(8.3)
Proceeds under revolvers	205.0	2.3
Payments under revolvers	0	(5.0)
Retirement of term loans	(180.0)	0
Payment of fees related to refinancing activities	0	(0.2)
Equity:
Option exercises	0.3	0.3
Net cash provided by (used in) financing activities	17.5	(13.2)
Effect of exchange rate changes on cash	1.9	(1.1)
Increase (decrease) in cash and cash equivalents	(55.6)	(10.2)
Cash and cash equivalents, beginning of period	247.6	355.6
Cash and cash equivalents, end of period	192.0	345.4
Supplemental disclosures of cash flow information:
Interest	93.8	101.3
Income taxes	19.4	32.2
Biomet, Inc. [Member]
Cash flows provided by (used in) operating activities:
Net income	7.3	31.1
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	122.1	120.4
Amortization and write off of deferred financing costs	2.8	3.6
Stock-based compensation expense	3.6	4.2
Provision for (recovery) of doubtful accounts receivable	(1.0)	0.1
Deferred income taxes	(29.8)	(61.0)
Other	(3.6)	(3.9)
Changes in operating assets and liabilities, net of acquired assets:
Accounts receivable	40.9	8.0
Inventories	(36.7)	(7.5)
Prepaid expenses	20.6	2.3
Accounts payable	(14.0)	(19.6)
Income taxes	4.0	17.0
Accrued interest	(16.6)	(16.2)
Accrued wages and commissions	(48.2)	(34.8)
Accrued expenses and other	(49.0)	7.1
Net cash provided by operating activities	2.4	50.8
Cash flows provided by (used in) investing activities:
Proceeds from sales/maturities of investments	0	9.5
Purchases of investments	(16.3)	(9.5)
Net proceeds from sale of assets	0	0.2
Capital expenditures	(60.8)	(46.5)
Acquisitions, net of cash acquired	(0.3)	(0.4)
Net cash used in investing activities	(77.4)	(46.7)
Debt:
Payments under European facilities	0	(2.3)
Payments under senior secured credit facilities	(7.8)	(8.3)
Proceeds under revolvers	205.0	2.3
Payments under revolvers	0	(5.0)
Retirement of term loans	(180.0)	0
Payment of fees related to refinancing activities	0	(0.2)
Equity:
Option exercises	0.3	0.3
Net cash provided by (used in) financing activities	17.5	(13.2)
Effect of exchange rate changes on cash	1.9	(1.1)
Increase (decrease) in cash and cash equivalents	(55.6)	(10.2)
Cash and cash equivalents, beginning of period	247.6	355.6
Cash and cash equivalents, end of period	192.0	345.4
Supplemental disclosures of cash flow information:
Interest	93.8	101.3
Income taxes	$ 19.4	$ 32.2